BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that the positive Phase I clinical data for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD) was accepted for publication by the peer-reviewed journal Vaccine on March 4, 2012, and the uncorrected proof is available online as of March 14, 2012. The article, entitled "Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trial," provides an in-depth look at the safety observation with preliminary immunogenicity data from the study, in which all three age groups (adult, children and infant) showed good safety and tolerance profiles.
In the Phase I clinical trial, the vaccine candidates were given to the adults first, starting from the lowest dosage to higher dosages. After the two inoculations were administered to the adults, a safety observation was conducted, and the safety evaluation report was reviewed by clinical experts as well as the Data Safety and Monitoring Committee (DSMC). Once safety was confirmed, inoculations were administered to the children, and the same procedure was followed before the infants were inoculated. This trial protocol was approved by the Ethics Committee.
The Phase I clinical trial showed that Sinovac's novel inactivated human EV71 vaccine was well tolerated in healthy volunteers, and the testing results on neutralizing antibody indicated good immunogenicity. Sinovac confirmed these data in the Phase II trial, which demonstrated that the EV71 vaccine demonstrated a good immunogenicity and a favorable safety profile with no vaccine-related serious adverse events.
Li Yan-Ping of the Center for Disease Control and Prevention of the Guangxi Zhuang Autonomous Region, and the principle investigator, stated, "The novel human EV71 inactivated vaccine was well tolerated in the healthy volunteers. For immune response, we observed that the seropositive rates of neutralizing antibody increased to 100% for all dosage groups after the second vaccination. With more than 90% of the reported HFMD cases occurring in children under five years old, an urgent need exists for a novel vaccine that is effective against human EV71 outbreaks. These results bring us one step closer to realizing that goal."Dr. Weidong Yin, Chairman, President and CEO, also commented, "The HFMD epidemic situation is still serious in China. However, there is no EV71 specific prevention method to help control the spread of HFMD. Both the Chinese government and the public have great expectations regarding vaccine development. We are pleased to have our Phase I clinical data published in the prestigious journal Vaccine. HFMD represents a significant unmet medical need as no pharmacological intervention has been proven to prevent or control this disease. Vaccination is expected to be the most effective measure to control the spread of the virus and to reduce associated morbidity and mortality." Yin continued: "We are advancing our EV71 vaccine as planned. In January 2012, we commenced our Phase III clinical trials before the HFMD outbreak season. Through the end of March 2012, approximately 10,000 healthy volunteers have been enrolled, and the two-shot inoculation schedule, at 0 and 28 days, and the blood collection on the 56 th day after the first inoculation have been completed in these volunteers. We began the observation and data collection phase since March 14, 2012, to assess the HFMD epidemic situation and to evaluate the efficacy of our novel vaccine. Currently, the Phase III trial is progressing on schedule and is on track to be completed in the first half of 2013. Meanwhile, the construction of the EV71 vaccine production plant is progressing well. The purpose of building the facility in parallel with the Phase III clinical research is to make sure that the vaccine can be provided to protect those at risk as soon as it's approved." About EV71
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.